Online inquiry

IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13867MR)

This product GTTS-WQ13867MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD3E&MS4A1 gene. The antibody can be applied in Chronic lymphocytic leukemia (CLL), Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_000733.4; NM_021950.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 916; 931
UniProt ID P07766; P11836
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD3E&MS4A1, REGN-1979(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13867MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ10820MR IVTScrip™ mRNA-Anti-PD-L1&TGFBR2, M7824(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA M7824
GTTS-WQ6293MR IVTScrip™ mRNA-Anti-CD274, CS-1001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CS-1001
GTTS-WQ13691MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA RC48
GTTS-WQ11511MR IVTScrip™ mRNA-Anti-FGFR3, MFGR1877S(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MFGR1877S
GTTS-WQ3532MR IVTScrip™ mRNA-Anti-APP, BART(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA BART
GTTS-WQ7151MR IVTScrip™ mRNA-Anti-CTGF, FG-3019(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA FG-3019
GTTS-WQ10997MR IVTScrip™ mRNA-Anti-CD79B, MCDS0593A(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA MCDS0593A
GTTS-WQ13769MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA REGN-1033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW